NRICM101

From Wikipedia, the free encyclopedia

NRICM101 (Chinese: 清冠一號; Taiwan: Chingguan Yihau; Mainland: Qīng-guān Yī-hào), is a treatment for COVID-19 developed in Taiwan using Traditional Chinese Medicine (TCM), created by the National Research Institute of Chinese Medicine (NRICM), a governmental body of Taiwan.[1] The prescription has gained legal approval in several countries, the first TCM recipe to do so for COVID-19 treatment.[2] In its native Taiwan, the treatment is used in conjunction with vaccinations.[3] Amongst the formulations available are RespireAid from Sun Ten (順天堂) [zh], and COVRelief from Chuang Song Zong (莊松榮) [zh].[4][5]

Formulation[edit]

NRICM101 contains 10 herbal medicinal components, including indigowoad root, fish mint, Chinese skullcap, houttuynia, and licorice.[4][6][7]

Method of action[edit]

According to the NRICM, the herbal medicine is supposed to work by preventing the SARS-CoV2 virus from binding with ACE2.[7] This would reduce the chance of severe illness.[5]

Distribution[edit]

On 2021 May 18, Taiwan licensed NRICM101 for distribution under emergency access policy. It became available as dietary supplement in the U.S., the UK, Australia, the EU.[4][5]

Studies and efficacy[edit]

Further reading[edit]

  • Keng-Chang Tsai; Yi-Chia Huang; Chia-Ching Liaw; Chia-I Tsai; Chun-Tang Chiou; Chien-Jung Lin; Wen-Chi Wei; Sunny Jui-Shan Lin; Yu-Hwei Tseng; Kuo-Ming Yeh; Yi-Ling Lin; Jia-Tsrong Jan; Jian-Jong Liang; Chun-Che Liao; Wen-Fei Chiou; Yao-Haur Kuo; Shen-Ming Lee; Ming-Yung Lee; Yi-Chang Su (January 2021). "A traditional Chinese medicine formula NRICM101 to target COVID-19 through multiple pathways: A bedside-to-bench study". Biomedicine & Pharmacotherapy. 133 (111037): 111037. doi:10.1016/j.biopha.2020.111037. PMC 7676327. PMID 33249281.
  • Yih-Dih Cheng; Chi-Cheng Lu; Yuan-Man Hsu; Fuu-Jen Tsai; Da-Tian Bau; Shih-Chang Tsai; Ching-Chang Cheng; Jen-Jyh Lin; Yuang-Yu Huang; Yu-Ning Juan; Yu-Jen Chiu; Sheng-Chu Kuo; Jai-Sing Yang; Lii-Tzu Wu (2022). "In silico and in vitro studies of Taiwan Chingguan Yihau (NRICM101) on TNF-α/IL-1β-induced Human Lung Cells". BioMedicine. 12 (3): 56–71. doi:10.37796/2211-8039.1378. PMC 9629402. PMID 36381194. S2CID 251943611. 8.

References[edit]

  1. ^ "Herbal formula lauded as COVID-19 treatment". Taipei Times. CNA. 25 April 2022.
  2. ^ "A TCM Prescription for Covid: Taiwan's NRICM101". New Southbound Policy Portal. Ministry of Foreign Affairs of the Republic of China (Taiwan). 25 April 2022.
  3. ^ Hungyin Tsai (September–October 2022). "The History of Vaccine Uptake in Taiwan". American Scientist. Vol. 110, no. 5. p. 292. doi:10.1511/2022.110.5.292.
  4. ^ a b c Huang Tzu-ti (27 May 2021). "Pharmaceutical donates COVID herbal drug to hospitals in Taiwan". Taiwan News.
  5. ^ a b c Huang Tzu-ti (15 March 2021). "Herbal COVID medicine from Taiwan takes West by storm". Taiwan News.
  6. ^ Ho ST, Tsai YN, Su YC (July 2023). "The development and application of NRICM101 and NRICM102 for the treatment of COVID-19". Journal of the Formosan Medical Association. 122 (7): 525–527. doi:10.1016/j.jfma.2023.04.015. PMC 10130323. PMID 37147240.
  7. ^ a b G. Chen (4 October 2022). "RespireAid Tested Effective Against COVID-19 Variants 清冠一號最新研究 抗新冠變異株更有效". 公視新聞網 PNN. Public Television Service.

External links[edit]


Stub icon

This Taiwan-related article is a stub. You can help Wikipedia by expanding it.

Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

Stub icon

This China-related article is a stub. You can help Wikipedia by expanding it.

Stub icon

This article about the COVID-19 pandemic is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=NRICM101&oldid=1220174863"